Detailed price information for Medicenna Therapeutics Corp (MDNAF) from The Globe and Mail including charting and trades.

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...

The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...

ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...

During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...

ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ: Culver City, California Friday, January 16, 2026, 15:00 Hrs [IST ...

Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...

GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...